Papa John’s Slides on Front Office Changes
Papa John’s International, Inc. (NASDAQ: PZZA) shares declined in price Thursday, on the promotion of Caroline Miller Oyler to Chief Administrative Officer, effective immediately. Oyler has served as the company’s Chief Legal and Risk Officer since 2018 and will continue in her role as Corporate Secretary.In her expanded role, Oyler will now oversee human resources and culture (People Experience), legal, risk, safety and security, internal audit and facilities. The consolidation of these key business support functions is designed to enable efficiency and closer collaboration across teams.“Caroline has been an integral part of Papa Johns for more than two decades,” said CEO Todd Penegor. “Her deep institutional knowledge and proven leadership across multiple functions make her ideally suited to lead this newly formed role as we continue to transform our company for long-term growth.”Oyler has been with Papa Johns for 26 years and has served as interim leader of the Human Resources function on three occasions, from 2008 to 2009, 2018 to 2019, and in 2022.Papa John’s is co-headquartered in Atlanta, Ga. and Louisville, Ky. and is the world's third-largest pizza delivery company with more than 6,000 restaurants in approximately 50 countries and territories. PZZA shares handed back $1.09, or 2.3%, early Thursday to $46.00
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


